| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
|
J Clin Oncol
|
2005
|
7.77
|
|
2
|
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
|
J Clin Oncol
|
2006
|
7.24
|
|
3
|
Revision of the American Joint Committee on Cancer staging system for breast cancer.
|
J Clin Oncol
|
2002
|
6.51
|
|
4
|
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
|
J Clin Oncol
|
2005
|
3.83
|
|
5
|
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
|
Clin Cancer Res
|
2007
|
3.62
|
|
6
|
The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial.
|
Cancer
|
2004
|
3.50
|
|
7
|
Breast cancer. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2009
|
3.17
|
|
8
|
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions.
|
J Natl Cancer Inst
|
2012
|
3.16
|
|
9
|
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual.
|
Surg Clin North Am
|
2003
|
2.82
|
|
10
|
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
|
Clin Cancer Res
|
2002
|
2.66
|
|
11
|
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
|
J Clin Oncol
|
2011
|
2.51
|
|
12
|
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
|
J Clin Oncol
|
2005
|
2.39
|
|
13
|
Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival.
|
J Clin Oncol
|
2003
|
2.19
|
|
14
|
Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers.
|
J Natl Cancer Inst
|
2003
|
2.11
|
|
15
|
Breast carcinoma during pregnancy. International recommendations from an expert meeting.
|
Cancer
|
2006
|
2.04
|
|
16
|
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.
|
Cancer
|
2003
|
2.01
|
|
17
|
Breast cancer treatment guidelines in older women.
|
J Clin Oncol
|
2005
|
1.97
|
|
18
|
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
|
J Natl Compr Canc Netw
|
2006
|
1.88
|
|
19
|
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
|
Cancer
|
2012
|
1.75
|
|
20
|
Selecting high priority quality measures for breast cancer quality improvement.
|
Med Care
|
2008
|
1.70
|
|
21
|
Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
|
J Clin Oncol
|
2014
|
1.68
|
|
22
|
Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
|
Cancer
|
2006
|
1.54
|
|
23
|
Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma.
|
Cancer
|
2005
|
1.45
|
|
24
|
Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.
|
Lancet Oncol
|
2009
|
1.37
|
|
25
|
The impact of pregnancy on breast cancer outcomes in women<or=35 years.
|
Cancer
|
2009
|
1.28
|
|
26
|
Future directions of bone-targeted therapy for metastatic breast cancer.
|
Nat Rev Clin Oncol
|
2010
|
1.27
|
|
27
|
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
|
Breast Cancer Res
|
2012
|
1.26
|
|
28
|
Biology of bone metastases.
|
Cancer Control
|
2012
|
1.25
|
|
29
|
Multidisciplinary management of breast cancer concurrent with pregnancy.
|
J Am Coll Surg
|
2002
|
1.25
|
|
30
|
Patient perspectives on breast cancer treatment plan and summary documents in community oncology care: a pilot program.
|
Cancer
|
2012
|
1.25
|
|
31
|
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2012
|
1.23
|
|
32
|
The impact of breast reconstruction on the delivery of chemotherapy.
|
Cancer
|
2010
|
1.20
|
|
33
|
Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
|
J Clin Oncol
|
2007
|
1.18
|
|
34
|
Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy.
|
Clin Breast Cancer
|
2005
|
1.16
|
|
35
|
The effect of age on delay in diagnosis and stage of breast cancer.
|
Oncologist
|
2012
|
1.15
|
|
36
|
The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers.
|
J Clin Oncol
|
2006
|
1.13
|
|
37
|
Conservative surgery and chemotherapy for breast carcinoma during pregnancy.
|
Surgery
|
2002
|
1.12
|
|
38
|
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.12
|
|
39
|
FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer.
|
Oncologist
|
2011
|
1.12
|
|
40
|
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
|
Cancer
|
2004
|
1.03
|
|
41
|
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
|
J Clin Oncol
|
2004
|
1.02
|
|
42
|
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
|
Clin Cancer Res
|
2002
|
1.01
|
|
43
|
Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?
|
Breast Cancer Res Treat
|
2006
|
0.98
|
|
44
|
Breast cancer and pregnancy: current concepts in diagnosis and treatment.
|
Oncologist
|
2010
|
0.98
|
|
45
|
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
|
Clin Cancer Res
|
2002
|
0.98
|
|
46
|
NCCN Task Force Report: Bone Health and Cancer Care.
|
J Natl Compr Canc Netw
|
2006
|
0.96
|
|
47
|
Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.95
|
|
48
|
Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis.
|
Oncologist
|
2011
|
0.94
|
|
49
|
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
|
Breast J
|
2002
|
0.93
|
|
50
|
Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.
|
J Clin Oncol
|
2008
|
0.93
|
|
51
|
Invasive breast cancer.
|
J Natl Compr Canc Netw
|
2007
|
0.92
|
|
52
|
Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.
|
J Natl Compr Canc Netw
|
2009
|
0.92
|
|
53
|
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
|
Cancer
|
2005
|
0.90
|
|
54
|
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
|
Cancer
|
2006
|
0.90
|
|
55
|
Time to diagnosis and breast cancer stage by race/ethnicity.
|
Breast Cancer Res Treat
|
2012
|
0.90
|
|
56
|
Aromatase inhibitors in postmenopausal breast cancer patients.
|
J Natl Compr Canc Netw
|
2005
|
0.89
|
|
57
|
Breast cancer diagnosis during pregnancy.
|
Womens Health (Lond Engl)
|
2009
|
0.89
|
|
58
|
Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know?
|
J Clin Oncol
|
2013
|
0.88
|
|
59
|
A prospective study of bone tumor response assessment in metastatic breast cancer.
|
Clin Breast Cancer
|
2012
|
0.87
|
|
60
|
Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004.
|
Cancer
|
2009
|
0.87
|
|
61
|
Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules.
|
Cancer
|
2006
|
0.86
|
|
62
|
Wound complications from surgery in pregnancy-associated breast cancer (PABC).
|
Breast Dis
|
2010
|
0.85
|
|
63
|
Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ.
|
Cancer
|
2012
|
0.85
|
|
64
|
Breast cancer.
|
J Natl Compr Canc Netw
|
2005
|
0.85
|
|
65
|
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
|
Cancer
|
2004
|
0.84
|
|
66
|
Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer.
|
Clin Breast Cancer
|
2004
|
0.84
|
|
67
|
Bone biology and the role of the RANK ligand pathway.
|
Oncology (Williston Park)
|
2009
|
0.84
|
|
68
|
Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer.
|
Oncologist
|
2013
|
0.84
|
|
69
|
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
|
Cancer
|
2005
|
0.83
|
|
70
|
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.
|
Oncologist
|
2011
|
0.82
|
|
71
|
Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study.
|
Cancer
|
2002
|
0.81
|
|
72
|
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
|
Cancer
|
2011
|
0.81
|
|
73
|
Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer.
|
Oncologist
|
2011
|
0.80
|
|
74
|
Comparison of baseline dietary intake of Hispanic and matched non-Hispanic white breast cancer survivors enrolled in the Women's Healthy Eating and Living study.
|
J Am Diet Assoc
|
2008
|
0.78
|
|
75
|
Pregnancy after the diagnosis of breast cancer.
|
Clin Breast Cancer
|
2006
|
0.78
|
|
76
|
Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer.
|
Clin Breast Cancer
|
2008
|
0.77
|
|
77
|
The safety of chemotherapy for breast cancer patients with hepatitis C virus infection.
|
J Cancer
|
2013
|
0.76
|
|
78
|
Commentary: Ovarian function does not equal fertility does not equal babies.
|
Oncologist
|
2007
|
0.75
|